ARWR Arrowhead Pharmaceuticals Inc

USD 25.84 -0.66 -2.490566
Icon

Arrowhead Pharmaceuticals Inc (ARWR) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 25.84

-0.66 (-2.49)%

USD 3.21B

1.15M

USD 57.11(+121.02%)

USD 47.50 (+83.82%)

Icon

ARWR

Arrowhead Pharmaceuticals Inc (USD)
COMMON STOCK | NSD
USD 25.84
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 3.21B

USD 47.50 (+83.82%)

USD 25.84

Arrowhead Pharmaceuticals Inc (ARWR) Stock Forecast

Show ratings and price targets of :
USD 57.11
(+121.02%)

Based on the Arrowhead Pharmaceuticals Inc stock forecast from 6 analysts, the average analyst target price for Arrowhead Pharmaceuticals Inc is USD 57.11 over the next 12 months. Arrowhead Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arrowhead Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Arrowhead Pharmaceuticals Inc’s stock price was USD 25.84. Arrowhead Pharmaceuticals Inc’s stock price has changed by +8.07% over the past week, +12.79% over the past month and -26.88% over the last year.

No recent analyst target price found for Arrowhead Pharmaceuticals Inc
No recent average analyst rating found for Arrowhead Pharmaceuticals Inc

Company Overview Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and ch...Read More

https://arrowheadpharma.com

177 East Colorado Boulevard, Pasadena, CA, United States, 91105

525

September

USD

USA

Adjusted Closing Price for Arrowhead Pharmaceuticals Inc (ARWR)

Loading...

Unadjusted Closing Price for Arrowhead Pharmaceuticals Inc (ARWR)

Loading...

Share Trading Volume for Arrowhead Pharmaceuticals Inc Shares

Loading...

Compare Performance of Arrowhead Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ARWR

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Arrowhead Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +1.70 (+0.35%) USD124.65B 31.35 20.00

ETFs Containing ARWR

Symbol Name ARWR's Weight Expense Ratio Price(Change) Market Cap
GNOG:LSE
Global X Genomics & Biote.. 4.23 % 0.50 % -0.11 (-1.90%) USD6.38M

Frequently Asked Questions About Arrowhead Pharmaceuticals Inc (ARWR) Stock

Based on ratings from 6 analysts Arrowhead Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and 3 hold ratings.

Unfortunately we do not have enough data on ARWR's stock to indicate if its a good dividend stock.

Based on targets from 6 analysts, the average taret price for ARWR is USD 57.11 over the next 12 months. The maximum analyst target price is USD 90 while the minimum anlayst target price is USD 27.

ARWR stock's Price/Earning ratio is 478.56. Our analysis grades ARWR stock's Price / Earning ratio at F. This means that ARWR stock's Price/Earning ratio is above 98% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ARWR may be a overvalued for its sector.

The last closing price of ARWR's stock was USD 25.84.

The most recent market capitalization for ARWR is USD 3.21B.

Based on targets from 6 analysts, the average taret price for ARWR is projected at USD 57.11 over the next 12 months. This means that ARWR's stock price may go up by +121.02% over the next 12 months.

Following are ETFs with the highest allocation to Arrowhead Pharmaceuticals Inc's stock :

GNOG:LSE

As per our most recent records Arrowhead Pharmaceuticals Inc has 525 Employees.

Arrowhead Pharmaceuticals Inc's registered address is 177 East Colorado Boulevard, Pasadena, CA, United States, 91105. You can get more information about it from Arrowhead Pharmaceuticals Inc's website at https://arrowheadpharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...